Pharmabcine Inc.

Jinsang Yoo

Weon Sup Lee

Sang Soon Byun

Hyuk Jin Lee

Sung-Woo Kim

Jin-San Yoo

Jae Bong Yoon

Eun Hee Lee

Sang Ryeol Shim

Miju Park

Youngae Lee

Jinhee Choi

Seon Young Lee

Do Yun Kim

Do-Yun Kim

Jin San Yoo

Nam Ye Kim

Jong Geun Jeong

Seon Hwan Oh

Do-yun Kim

Sungho Ahn

Keunhee Oh

Mi Ae Jeon

Kyoung Hee Nahm

Shin Ae Yi

Boyoung Jeong

Yeon Ju Kim

Ji Hye Jeong

Hyuk Joon Lee

Ju Ryoung Nam

Disclosed are an anti-PD-L1 antibody or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, a pharmaceutical composition for preventing or treating cancer containing the same, and a composition for co-administration with an antibody other than an antibody binding to PD-L1, containing the same.

Anti-PD-L1 antibody and use thereof

The present disclosure relates to an antibody specifically binding to epidermal growth factor receptor variant III (EGFRvIII), to nucleic acid coding the antibody, to a vector comprising the nucleic acid, to a host cell, to a preparation method of the antibody, and to a pharmaceutical composition comprising the antibody as an active ingredient for treating a cancer or a tumor.

EGFRvIII antibody and composition comprising same

Provided are an antibody specifically bound to c-Met (c-Met-specific antibody) or fragments thereof, and more specifically, a fully human antibody having high affinity and specificity to c-Met isolated from human Fv(ScFv) phage library, a polynucleotide encoding the antibody, a recombinant vector containing the polynucleotide, a cell transformed with the recombinant vector, and a method of producing the c-Met-specific antibody by culturing the cell, wherein the c-Met-specific antibody may effectively control activity of c-Met in vivo.

Human antibody specific to c-Met and preparation method thereof

Growing community of inventors

Daejeon, South Korea

Jinsang Yoo